Table 1.
Baseline Characteristics of the Study Participants
| Teriparatide (n = 10) | Placebo (n = 11) | P Value | |
|---|---|---|---|
| Age, y | 47.0 ± 2.7 | 47.1 ± 2.3 | .98 |
| BMI, kg/m2 | 17.6 ± 0.4 | 16.6 ± 0.4 | .08 |
| Weight, kg | 47.2 ± 2.1 | 45.4 ± 1.4 | .47 |
| Height, cma | 163.5 ± 2.3 | 165.5 ± 1.8 | .86 |
| Percentage of ideal body weight | 80.1 ± 2 | 74.7 ± 1.8 | .06 |
| Years since onset of anorexia nervosa (self-reported) | 20.4 ± 3.7 | 18.0 ± 4.3 | .70 |
| Mean systolic blood pressure, mm Hg | 106 ± 5 | 105 ± 4 | .90 |
| Mean diastolic blood pressure, mm Hg | 67 ± 4 | 69 ± 3 | .75 |
| Self-reported hours of exercise per weeka | 7.2 ± 2.3 | 8.4 ± 2.9 | .97 |
| Amenorrhea, n | 8 | 7 | .64 |
| Subjects reporting current use of antidepressant medications, n | 8 | 7 | .64 |
| Subjects obtaining <1200 mg Ca daily (through diet and/or supplements), n | 2 | 3 | .99 |
| Subjects obtaining <400 IU vitamin D daily (through diet and/or supplements), n | 2 | 5 | .35 |
| BMD of PA spine, g/cm2 | 0.77 ± 0.02 | 0.81 ± 0.03 | .28 |
| PA spine T-score | −2.6 ± 0.2 | −2.1 ± 0.3 | .29 |
| BMD of lateral spine, g/cm2 | 0.53 ± 0.03 | 0.57 ± 0.01 | .22 |
| Lateral spine T-score | −3.5 ± 0.3 | −3.0 ± 0.2 | .24 |
| BMD of total hip, g/cm2 | 0.71 ± 0.04 | 0.69 ± 0.02 | .72 |
| Total hip T-scorea | −1.9 ± 0.4 | −2.0 ± 0.1 | .60 |
| BMD of femoral neck, g/cm2a | 0.60 ± 0.03 | 0.60 ± 0.02 | .70 |
| Femoral neck T-scorea | −2.3 ± 0.3 | −2.3 ± 0.1 | .57 |
| Past use of bisphosphonates, n | 4 | 5 | .99 |
| 25-OH vitamin D, ng/mL | 31.1 ± 3.3 | 40.4 ± 4.2 | .1 |
| IGF-1, ng/mL | 152 ± 18 | 104 ± 9 | .03 |
| P1NP, ng/mLa | 63 ± 8 | 37 ± 6 | .02 |
| CTX, ng/mL | 0.55 ± 0.12 | 0.53 ± 0.08 | .88 |
| Sclerostin, ng/mL | 0.59 ± 0.05 | 0.69 ± 0.10 | .39 |
a
Wilcoxon test used to analyze between-group differences.